The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
Budesonide (BUD), sold under the brand name Pulmicort among others, is a steroid medication. It is available as an inhaler, pill, and Injectable Suspension. The inhaled form is used in the long term management of asthma and chronic obstructive pulmonary disease (COPD). The Injectable Suspension is used for allergic rhinitis and nasal polyps. The pills in a delayed release form may be used for inflammatory bowel disease including Crohn's disease, ulcerative colitis and microscopic colitis. Statistic for budesonide in this report includes three product types: Injectable Suspension, inhaler and Inhalation Powder.
The global Budesonide market was valued at US$ 8203 million in 2023 and is anticipated to reach US$ 10250 million by 2030, witnessing a CAGR of 3.2% during the forecast period 2024-2030.
North America is the largest market with about 36% revenue market share. Followed by Asia-Pacific and Europe, accounting for about 60% revenue market share.
The key players are AstraZeneca, Teva, Mylan, Sandoz, Cosmo Pharmaceuticals, Salix, Chiesi Farmaceutici, Orion Corporation, Cipla, Synmosa Biopharma, Lunan Better Pharma, Shanghai Sine Promod etc. AstraZeneca is the largest manufacturer with about 56% revenue market share.
This report aims to provide a comprehensive presentation of the global market for Budesonide, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Budesonide.
Report Scope
The Budesonide market size, estimations, and forecasts are provided in terms of sales volume (M Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Budesonide market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Budesonide manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AstraZeneca
Teva
Mylan
Sandoz
Cosmo Pharmaceuticals
Salix
Chiesi Farmaceutici
Orion Corporation
Cipla
Synmosa Biopharma
Lunan Better Pharma
Shanghai Sine Promod
Segment by Type
Injectable Suspension
Aerosols
Inhalation Powder
Tablet and Capsule
Segment by Application
Respiratory Disease Treatment
Nose Disease Treatment
Inflammatory Bowel Disease Treatment
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Budesonide manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Budesonide in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Budesonide (BUD), sold under the brand name Pulmicort among others, is a steroid medication. It is available as an inhaler, pill, and Injectable Suspension. The inhaled form is used in the long term management of asthma and chronic obstructive pulmonary disease (COPD). The Injectable Suspension is used for allergic rhinitis and nasal polyps. The pills in a delayed release form may be used for inflammatory bowel disease including Crohn's disease, ulcerative colitis and microscopic colitis. Statistic for budesonide in this report includes three product types: Injectable Suspension, inhaler and Inhalation Powder.
The global Budesonide market was valued at US$ 8203 million in 2023 and is anticipated to reach US$ 10250 million by 2030, witnessing a CAGR of 3.2% during the forecast period 2024-2030.
North America is the largest market with about 36% revenue market share. Followed by Asia-Pacific and Europe, accounting for about 60% revenue market share.
The key players are AstraZeneca, Teva, Mylan, Sandoz, Cosmo Pharmaceuticals, Salix, Chiesi Farmaceutici, Orion Corporation, Cipla, Synmosa Biopharma, Lunan Better Pharma, Shanghai Sine Promod etc. AstraZeneca is the largest manufacturer with about 56% revenue market share.
This report aims to provide a comprehensive presentation of the global market for Budesonide, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Budesonide.
Report Scope
The Budesonide market size, estimations, and forecasts are provided in terms of sales volume (M Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Budesonide market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Budesonide manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AstraZeneca
Teva
Mylan
Sandoz
Cosmo Pharmaceuticals
Salix
Chiesi Farmaceutici
Orion Corporation
Cipla
Synmosa Biopharma
Lunan Better Pharma
Shanghai Sine Promod
Segment by Type
Injectable Suspension
Aerosols
Inhalation Powder
Tablet and Capsule
Segment by Application
Respiratory Disease Treatment
Nose Disease Treatment
Inflammatory Bowel Disease Treatment
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Budesonide manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Budesonide in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Budesonide Market Overview
1.1 Product Overview and Scope of Budesonide
1.2 Budesonide Segment by Type
1.2.1 Global Budesonide Market Value Comparison by Type (2024-2030)
1.2.2 Injectable Suspension
1.2.3 Aerosols
1.2.4 Inhalation Powder
1.2.5 Tablet and Capsule
1.3 Budesonide Segment by Application
1.3.1 Global Budesonide Market Value by Application: (2024-2030)
1.3.2 Respiratory Disease Treatment
1.3.3 Nose Disease Treatment
1.3.4 Inflammatory Bowel Disease Treatment
1.3.5 Others
1.4 Global Budesonide Market Size Estimates and Forecasts
1.4.1 Global Budesonide Revenue 2019-2030
1.4.2 Global Budesonide Sales 2019-2030
1.4.3 Global Budesonide Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Budesonide Market Competition by Manufacturers
2.1 Global Budesonide Sales Market Share by Manufacturers (2019-2024)
2.2 Global Budesonide Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Budesonide Average Price by Manufacturers (2019-2024)
2.4 Global Budesonide Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Budesonide, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Budesonide, Product Type & Application
2.7 Budesonide Market Competitive Situation and Trends
2.7.1 Budesonide Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Budesonide Players Market Share by Revenue
2.7.3 Global Budesonide Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Budesonide Retrospective Market Scenario by Region
3.1 Global Budesonide Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Budesonide Global Budesonide Sales by Region: 2019-2030
3.2.1 Global Budesonide Sales by Region: 2019-2024
3.2.2 Global Budesonide Sales by Region: 2025-2030
3.3 Global Budesonide Global Budesonide Revenue by Region: 2019-2030
3.3.1 Global Budesonide Revenue by Region: 2019-2024
3.3.2 Global Budesonide Revenue by Region: 2025-2030
3.4 North America Budesonide Market Facts & Figures by Country
3.4.1 North America Budesonide Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Budesonide Sales by Country (2019-2030)
3.4.3 North America Budesonide Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Budesonide Market Facts & Figures by Country
3.5.1 Europe Budesonide Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Budesonide Sales by Country (2019-2030)
3.5.3 Europe Budesonide Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Budesonide Market Facts & Figures by Country
3.6.1 Asia Pacific Budesonide Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Budesonide Sales by Country (2019-2030)
3.6.3 Asia Pacific Budesonide Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Budesonide Market Facts & Figures by Country
3.7.1 Latin America Budesonide Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Budesonide Sales by Country (2019-2030)
3.7.3 Latin America Budesonide Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Budesonide Market Facts & Figures by Country
3.8.1 Middle East and Africa Budesonide Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Budesonide Sales by Country (2019-2030)
3.8.3 Middle East and Africa Budesonide Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Budesonide Sales by Type (2019-2030)
4.1.1 Global Budesonide Sales by Type (2019-2024)
4.1.2 Global Budesonide Sales by Type (2025-2030)
4.1.3 Global Budesonide Sales Market Share by Type (2019-2030)
4.2 Global Budesonide Revenue by Type (2019-2030)
4.2.1 Global Budesonide Revenue by Type (2019-2024)
4.2.2 Global Budesonide Revenue by Type (2025-2030)
4.2.3 Global Budesonide Revenue Market Share by Type (2019-2030)
4.3 Global Budesonide Price by Type (2019-2030)
5 Segment by Application
5.1 Global Budesonide Sales by Application (2019-2030)
5.1.1 Global Budesonide Sales by Application (2019-2024)
5.1.2 Global Budesonide Sales by Application (2025-2030)
5.1.3 Global Budesonide Sales Market Share by Application (2019-2030)
5.2 Global Budesonide Revenue by Application (2019-2030)
5.2.1 Global Budesonide Revenue by Application (2019-2024)
5.2.2 Global Budesonide Revenue by Application (2025-2030)
5.2.3 Global Budesonide Revenue Market Share by Application (2019-2030)
5.3 Global Budesonide Price by Application (2019-2030)
6 Key Companies Profiled
6.1 AstraZeneca
6.1.1 AstraZeneca Corporation Information
6.1.2 AstraZeneca Description and Business Overview
6.1.3 AstraZeneca Budesonide Sales, Revenue and Gross Margin (2019-2024)
6.1.4 AstraZeneca Budesonide Product Portfolio
6.1.5 AstraZeneca Recent Developments/Updates
6.2 Teva
6.2.1 Teva Corporation Information
6.2.2 Teva Description and Business Overview
6.2.3 Teva Budesonide Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Teva Budesonide Product Portfolio
6.2.5 Teva Recent Developments/Updates
6.3 Mylan
6.3.1 Mylan Corporation Information
6.3.2 Mylan Description and Business Overview
6.3.3 Mylan Budesonide Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Mylan Budesonide Product Portfolio
6.3.5 Mylan Recent Developments/Updates
6.4 Sandoz
6.4.1 Sandoz Corporation Information
6.4.2 Sandoz Description and Business Overview
6.4.3 Sandoz Budesonide Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Sandoz Budesonide Product Portfolio
6.4.5 Sandoz Recent Developments/Updates
6.5 Cosmo Pharmaceuticals
6.5.1 Cosmo Pharmaceuticals Corporation Information
6.5.2 Cosmo Pharmaceuticals Description and Business Overview
6.5.3 Cosmo Pharmaceuticals Budesonide Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Cosmo Pharmaceuticals Budesonide Product Portfolio
6.5.5 Cosmo Pharmaceuticals Recent Developments/Updates
6.6 Salix
6.6.1 Salix Corporation Information
6.6.2 Salix Description and Business Overview
6.6.3 Salix Budesonide Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Salix Budesonide Product Portfolio
6.6.5 Salix Recent Developments/Updates
6.7 Chiesi Farmaceutici
6.6.1 Chiesi Farmaceutici Corporation Information
6.6.2 Chiesi Farmaceutici Description and Business Overview
6.6.3 Chiesi Farmaceutici Budesonide Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Chiesi Farmaceutici Budesonide Product Portfolio
6.7.5 Chiesi Farmaceutici Recent Developments/Updates
6.8 Orion Corporation
6.8.1 Orion Corporation Corporation Information
6.8.2 Orion Corporation Description and Business Overview
6.8.3 Orion Corporation Budesonide Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Orion Corporation Budesonide Product Portfolio
6.8.5 Orion Corporation Recent Developments/Updates
6.9 Cipla
6.9.1 Cipla Corporation Information
6.9.2 Cipla Description and Business Overview
6.9.3 Cipla Budesonide Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Cipla Budesonide Product Portfolio
6.9.5 Cipla Recent Developments/Updates
6.10 Synmosa Biopharma
6.10.1 Synmosa Biopharma Corporation Information
6.10.2 Synmosa Biopharma Description and Business Overview
6.10.3 Synmosa Biopharma Budesonide Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Synmosa Biopharma Budesonide Product Portfolio
6.10.5 Synmosa Biopharma Recent Developments/Updates
6.11 Lunan Better Pharma
6.11.1 Lunan Better Pharma Corporation Information
6.11.2 Lunan Better Pharma Budesonide Description and Business Overview
6.11.3 Lunan Better Pharma Budesonide Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Lunan Better Pharma Budesonide Product Portfolio
6.11.5 Lunan Better Pharma Recent Developments/Updates
6.12 Shanghai Sine Promod
6.12.1 Shanghai Sine Promod Corporation Information
6.12.2 Shanghai Sine Promod Budesonide Description and Business Overview
6.12.3 Shanghai Sine Promod Budesonide Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Shanghai Sine Promod Budesonide Product Portfolio
6.12.5 Shanghai Sine Promod Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Budesonide Industry Chain Analysis
7.2 Budesonide Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Budesonide Production Mode & Process
7.4 Budesonide Sales and Marketing
7.4.1 Budesonide Sales Channels
7.4.2 Budesonide Distributors
7.5 Budesonide Customers
8 Budesonide Market Dynamics
8.1 Budesonide Industry Trends
8.2 Budesonide Market Drivers
8.3 Budesonide Market Challenges
8.4 Budesonide Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
